Skin Activating Treatment Ampoule

The Skin Activating Treatment Ampoule introduces Totipotent Prostembryona Factor® (TPF) technology to professional clinic practice — delivering pluripotent growth factor signalling comparable to stem cell-conditioned media, without the regulatory complexity of live cell therapies. Recognised at the 2023 COSMOTRENDS Innovation Awards for breakthrough ingredient science.

Technical Specifications

Clinical Q&A

Q: What is Totipotent Prostembryona Factor® (TPF) and how does it activate skin cells?
A: TPF is a proprietary bioactive extract derived from fertilised fish roe at the totipotent embryonic stage — when cells possess maximal developmental pluripotency. The extract is rich in naturally occurring growth factors (EGF-like peptides, FGF analogues, IGF-1 precursors) and cellular signalling proteins that bind surface receptors on dermal fibroblasts and epidermal keratinocytes. TPF binding triggers PI3K/AKT and MAPK/ERK intracellular cascades, stimulating fibroblast proliferation and collagen I/III gene transcription — restoring the extracellular matrix architecture degraded by photoageing and chronological ageing.

Q: How does Snow Algae Extract complement the TPF growth factor complex?
A: Snow Algae (Coenochloris signiensis) is a psychrophilic microalgae that survives in extreme UV and cold conditions through production of cryoprotective polysaccharides and Klotho protein-activating compounds. Klotho activation in skin cells counteracts the cellular senescence pathway, extending fibroblast replicative lifespan and reducing senescence-associated secretory phenotype (SASP) inflammatory signalling. Combined with TPF's proliferative stimulus, Snow Algae extract produces a dual anti-ageing effect: active regeneration plus suppression of senescence-driven inflammation.

Q: What skin conditions show the strongest response to the Skin Activating Treatment Ampoule?
A: Photoaged skin with fine rhytids, reduced elasticity, and devitalised complexion responds most consistently. Post-inflammatory conditions following laser resurfacing, chemical peels, or microneedling benefit from the growth factor stimulus during the proliferative repair phase. Skin laxity associated with weight loss or hormonal changes (peri/post-menopausal skin) also responds to fibroblast-activating protocols.

Q: How does TPF differ from human-derived placenta extracts or stem cell conditioned media?
A: Unlike human-derived biologics that carry xenogeneic transfer and regulatory concerns, TPF is derived from marine (fish) embryonic extract — avoiding ethical constraints associated with mammalian placental products. The growth factor profile is functionally analogous to human EGF and FGF families in receptor-binding activity, but the marine-origin source allows cosmetic (non-medicinal) regulatory classification. This permits clinic application without the prescribing framework required for human cell-derived injectables.

Q: What regulatory standards and quality systems govern this product?
A: Manufactured under ISO 9001:2015 quality management. TPF (Fertilised Roe Extract), Snow Algae Extract, and Sodium Hyaluronate are ASEAN Cosmetic Directive-listed ingredients notified to Singapore's HSA under the Cosmetic Products (Control) Act. The ampoule format is classified as a cosmetic preparation, not a medicinal injectable, when administered topically or via approved aesthetic mesotherapy protocols by licensed practitioners.

Regulatory & Standards References

• ISO 9001:2015 — Quality management system applied to Skin Activating Treatment Ampoule manufacturing
• HSA Singapore / ASEAN Cosmetic Directive — All actives notified as cosmetic ingredients; Fertilised Roe Extract, Snow Algae Extract, Sodium Hyaluronate approved
• 2023 COSMOTRENDS Innovation Award — International cosmetic industry recognition for TPF ingredient technology
• ICH Q1A(R2) — Stability testing guidance applicable to single-use ampoule storage claims